Geron Corporation's (GERN) CEO Dr. John Scarlett on Q2 2022 Results - Earnings Call Transcript

Geron Corporation (NASDAQ:GERN) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET

Company Participants

Aron Feingold - Vice President, Investor Relations and Corporate Communications
Dr. John Scarlett - Chairman and CEO
Olivia Bloom - Executive Vice President, Finance and CFO and Treasurer
Dr. Faye Feller - Executive Vice President and CMO
Anil Kapur - Executive Vice President, Corporate Strategy and CCO

Conference Call Participants

Kalpit Patel - B. Riley Securities
Joel Beatty - Baird
Stephen Willey - Stifel
Gil Blum - Needham & Company

Operator

Good afternoon. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Geron Earnings Second Quarter 2022 Conference Call. All lines have been placed on mute to prevent any background noise and today’s conference is being recorded. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]

Thank you. Aron Feingold, Vice President of Investor Relations and Corporate Communications, you may now begin your conference.

Aron Feingold

Good afternoon, everyone. Welcome to the Geron Corporation second quarter 2022 conference call. I am Aron Feingold, Geron’s Vice President of Investor Relations and Corporate Communications. I am joined today by the following members of Geron’s management team, Dr. John Scarlett, Chairman and Chief Executive Officer; Olivia Bloom, Executive Vice President of Finance and Chief Financial Officer and Treasurer; Dr. Faye Feller, Executive Vice President and Chief Medical Officer; and Anil Kapur, Executive Vice President of Corporate Strategy and Chief Commercial Officer.

Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections, including those relating to the therapeutic potential and potential regulatory approval of imetelstat, anticipated clinical and commercial events and related timelines, the sufficiency of Geron’s financial resources